Tillkännagivande • Jul 03
CellSeed Inc. to Report Q2, 2026 Results on Aug 13, 2026 CellSeed Inc. announced that they will report Q2, 2026 results on Aug 13, 2026 Tillkännagivande • Apr 24
CellSeed Inc. to Report Q1, 2026 Results on May 13, 2026 CellSeed Inc. announced that they will report Q1, 2026 results on May 13, 2026 Tillkännagivande • Feb 16
CellSeed Inc., Annual General Meeting, Mar 25, 2026 CellSeed Inc., Annual General Meeting, Mar 25, 2026. Tillkännagivande • Dec 03
CellSeed Inc. to Report Fiscal Year 2025 Results on Feb 13, 2026 CellSeed Inc. announced that they will report fiscal year 2025 results on Feb 13, 2026 Tillkännagivande • Nov 20
CellSeed Inc. announced that it expects to receive ¥3.44 million in funding from Barclays Bank PLC, Investment Arm CellSeed Inc. announced a private placement by the Resolution of the Board of Directors to issue 86,000 25th Series of Stock Acquisition Rights at a price of ¥40 per stock acquisition right for gross proceeds of ¥3,440,000 on November 20, 2025. The transaction includes participation from Barclays Bank PLC. The Stock Acquisition Rights are convertible into 8,600,000 Ordinary Shares for gross proceeds of ¥3,268,000,000. The initial exercise price will be ¥380. On or after December 9, 2025, the exercise price will be revised on the effective date of each exercise request for the Stock Acquisition Rights to an amount equivalent to 97% of the closing price of the Company's common shares in regular trading on the Tokyo Stock Exchange on the trading day immediately preceding the revision date. If the revised exercise price based on this calculation falls below the minimum exercise price, the minimum exercise price will be the revised exercise price. The exercise period starts from from December 9, 2025 to December 8, 2027. New Risk • Oct 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change). New Risk • Oct 02
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥14.5b (US$99.1m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Minor Risk Market cap is less than US$100m (JP¥14.5b market cap, or US$99.1m). Tillkännagivande • Sep 27
CellSeed Inc. to Report Q3, 2025 Results on Nov 13, 2025 CellSeed Inc. announced that they will report Q3, 2025 results on Nov 13, 2025 Tillkännagivande • Jun 17
CellSeed Inc. to Report Q2, 2025 Results on Aug 13, 2025 CellSeed Inc. announced that they will report Q2, 2025 results on Aug 13, 2025 Tillkännagivande • Apr 08
CellSeed Inc. to Report Q1, 2025 Results on May 13, 2025 CellSeed Inc. announced that they will report Q1, 2025 results on May 13, 2025 New Risk • Mar 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (9.7% average weekly change). Tillkännagivande • Feb 13
CellSeed Inc., Annual General Meeting, Mar 25, 2025 CellSeed Inc., Annual General Meeting, Mar 25, 2025. New Risk • Dec 18
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥15.3b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (JP¥15.3b market cap, or US$99.7m). Tillkännagivande • Dec 03
CellSeed Inc. to Report Fiscal Year 2024 Results on Feb 13, 2025 CellSeed Inc. announced that they will report fiscal year 2024 results on Feb 13, 2025 Tillkännagivande • Oct 21
CellSeed Inc. to Report Nine Months, 2024 Results on Nov 14, 2024 CellSeed Inc. announced that they will report nine months, 2024 results on Nov 14, 2024 Tillkännagivande • Jun 22
CellSeed Inc. to Report Q2, 2024 Results on Aug 13, 2024 CellSeed Inc. announced that they will report Q2, 2024 results on Aug 13, 2024 New Risk • May 27
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2021 fiscal period end). Share price has been highly volatile over the past 3 months (10% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Market cap is less than US$100m (JP¥8.82b market cap, or US$56.3m). Tillkännagivande • Apr 26
CellSeed Inc. to Report Q1, 2024 Results on May 13, 2024 CellSeed Inc. announced that they will report Q1, 2024 results on May 13, 2024 Tillkännagivande • Feb 13
CellSeed Inc., Annual General Meeting, Mar 26, 2024 CellSeed Inc., Annual General Meeting, Mar 26, 2024. Tillkännagivande • Feb 08
MetaTech (AP) Inc. Files Lawsuit Against CellSeed Inc MetaTech (AP) Inc. has filed a lawsuit in Japan to confirm the existence of the contractual relationship between CellSeed Inc. about Collaboration Agreement etc. Details of occurrence (including the matter under dispute): CellSeed law firm commissioned the Baker McKenzie to send a lawyer's letter on 2023/12/19. In the absence of specific evidence and solely relying on media reports, they unilaterally claimed that company breached the Collaboration Agreement and terminated various contracts signed by both parties. To protect own interests, company has engaged Japanese lawyers to file a lawsuit in the Tokyo District Court in Japan to confirm the existence of the contractual relationship. Tillkännagivande • Jan 13
CellSeed Inc. to Report Fiscal Year 2023 Results on Feb 13, 2024 CellSeed Inc. announced that they will report fiscal year 2023 results on Feb 13, 2024 Tillkännagivande • Oct 24
CellSeed Inc. to Report Nine Months, 2023 Results on Nov 14, 2023 CellSeed Inc. announced that they will report nine months, 2023 results on Nov 14, 2023 Tillkännagivande • Jul 24
CellSeed Inc. to Report First Half, 2023 Results on Aug 14, 2023 CellSeed Inc. announced that they will report first half, 2023 results on Aug 14, 2023 Tillkännagivande • Jun 06
CellSeed Inc. announced that it has received ¥2.001 million in funding from Barclays Bank PLC, Investment Arm On June 5, 2023, CellSeed Inc. closed the transaction. Tillkännagivande • May 17
MetaTech (AP) Inc.,CHUN-LUNGWU and AlexCHEN agreed to acquire 12.69% stake in Up Cell Biomedical Co. from CellSeed Inc. (TSE:7776). MetaTech (AP) Inc.,CHUN-LUNGWU and AlexCHEN agreed to acquire 12.69% stake in Up Cell Biomedical Co. from CellSeed Inc. (TSE:7776) on May 15, 2023. Transfer execution date is June to late July 2023. Tillkännagivande • May 16
CellSeed Inc. announced that it expects to receive ¥2.001 million in funding from Barclays Bank PLC, Investment Arm CellSeed Inc. announced a private placement of of 69,000 24th stock acquisition rights at ¥29 per warrant for gross proceeds of ¥2,001,000 on May 15, 2023. The transaction will involve participation from returning investor Barclays Bank PLC, Investment Arm. The warrants will be exercisable into 6,900,000 common shares of the company. The minimum exercise price of warrants is ¥178 per share. The warrants will be exercisable from allocation date to June 12, 2025. The company will issue securities through third-party allotment. The transaction has been approved by the board of directors of the company. The transaction is expected to close between June 5, 2023 and June 12, 2023. Board Change • Apr 12
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 3 non-independent directors. Independent Outside Director Toshio Yamaguchi was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Tillkännagivande • Feb 15
CellSeed Inc., Annual General Meeting, Mar 28, 2023 CellSeed Inc., Annual General Meeting, Mar 28, 2023. Tillkännagivande • Jan 24
CellSeed Inc. to Report Fiscal Year 2022 Results on Feb 14, 2023 CellSeed Inc. announced that they will report fiscal year 2022 results on Feb 14, 2023 Tillkännagivande • Oct 27
CellSeed Inc. to Report Nine Months, 2022 Results on Nov 14, 2022 CellSeed Inc. announced that they will report nine months, 2022 results on Nov 14, 2022 Tillkännagivande • May 03
CellSeed Inc. to Report Q1, 2022 Results on May 12, 2022 CellSeed Inc. announced that they will report Q1, 2022 results on May 12, 2022 Reported Earnings • Apr 02
Full year 2021 earnings released: JP¥53.14 loss per share (vs JP¥55.25 loss in FY 2020) Full year 2021 results: JP¥53.14 loss per share. Revenue: JP¥161.0m (down 19% from FY 2020). Net loss: JP¥914.0m (loss widened 17% from FY 2020). Reported Earnings • Feb 17
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: JP¥53.14 loss per share (up from JP¥55.25 loss in FY 2020). Revenue: JP¥161.0m (down 19% from FY 2020). Net loss: JP¥914.0m (loss widened 17% from FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has fallen by 45% per year whereas the company’s share price has fallen by 41% per year. Tillkännagivande • Feb 15
CellSeed Inc., Annual General Meeting, Mar 25, 2022 CellSeed Inc., Annual General Meeting, Mar 25, 2022. Tillkännagivande • Jan 06
CellSeed Inc. announced that it has received ¥1.144 million in funding from Barclays Bank PLC, Investment Arm On January 5, 2022, CellSeed Inc. closed the transaction. Tillkännagivande • Dec 21
CellSeed Inc. announced that it expects to receive ¥1.144 million in funding from Barclays Bank PLC, Investment Arm CellSeed Inc. announced a private placement of 44,000 22nd stock acquisition rights at ¥26 per warrant for gross proceeds of ¥1,144,000 on December 20, 2021. The transaction will involve participation from Barclays Bank PLC, Investment Arm. The allotment date for warrants is January 5, 2022. The warrants will be exercisable into 4,400,000 common shares of the company at an initial exercise price of ¥196 per share, revisable. The minimum exercise price of warrants is ¥98 per share. The warrants will be exercisable From January 6, 2022 to January 5, 2023. The company will issue securities through third-party allotment. The transaction has been approved by board of directors of the company. Reported Earnings • Nov 13
Third quarter 2021 earnings released: JP¥12.24 loss per share (vs JP¥18.78 loss in 3Q 2020) The company reported a solid third quarter result with reduced losses, improved revenues and improved control over expenses. Third quarter 2021 results: Revenue: JP¥47.0m (up 88% from 3Q 2020). Net loss: JP¥217.0m (loss narrowed 20% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 45% per year but the company’s share price has only fallen by 34% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 18
Second quarter 2021 earnings released: JP¥14.17 loss per share (vs JP¥11.41 loss in 2Q 2020) The company reported a mediocre second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: JP¥40.0m (up 48% from 2Q 2020). Net loss: JP¥240.0m (loss widened 52% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 37% per year and the company’s share price has also fallen by 37% per year. Reported Earnings • May 16
First quarter 2021 earnings released: JP¥15.04 loss per share (vs JP¥13.69 loss in 1Q 2020) The company reported a mediocre first quarter result with increased losses and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: JP¥41.0m (up 32% from 1Q 2020). Net loss: JP¥246.0m (loss widened 35% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Feb 18
New 90-day high: JP¥290 The company is up 3.0% from its price of JP¥281 on 20 November 2020. The Japanese market is up 13% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. Tillkännagivande • Feb 16
CellSeed Inc., Annual General Meeting, Mar 26, 2021 CellSeed Inc., Annual General Meeting, Mar 26, 2021. Reported Earnings • Feb 14
Full year 2020 earnings released: JP¥55.25 loss per share (vs JP¥66.57 loss in FY 2019) The company reported a poor full year result with weaker revenues, weaker control over costs and no improvement to losses. Full year 2020 results: Revenue: JP¥199.0m (down 28% from FY 2019). Net loss: JP¥783.0m (flat on FY 2019). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 24% per year, which means it is performing significantly worse than earnings. Is New 90 Day High Low • Dec 28
New 90-day low: JP¥225 The company is down 35% from its price of JP¥348 on 29 September 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 7.0% over the same period. Is New 90 Day High Low • Dec 09
New 90-day low: JP¥264 The company is down 22% from its price of JP¥339 on 10 September 2020. The Japanese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 6.0% over the same period. Reported Earnings • Nov 15
Third quarter 2020 earnings released: JP¥18.78 loss per share The company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: JP¥25.0m (down 48% from 3Q 2019). Net loss: JP¥271.0m (loss widened 14% from 3Q 2019). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Nov 11
New 90-day low: JP¥295 The company is down 16% from its price of JP¥350 on 13 August 2020. The Japanese market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 1.0% over the same period. Tillkännagivande • Nov 10
CellSeed Inc. to Report Fiscal Year 2020 Results on Feb 14, 2021 CellSeed Inc. announced that they will report fiscal year 2020 results at 12:30 PM, GMT Standard Time on Feb 14, 2021 Is New 90 Day High Low • Oct 15
New 90-day low: JP¥319 The company is down 14% from its price of JP¥372 on 17 July 2020. The Japanese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 12% over the same period.